| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 28.14 | 1.2% | 8.9% |
| Total Income | 28.14 | 1.2% | 8.9% |
| Expenditure | 26.36 | 4.8% | 1.9% |
| PBT | — | ||
| Net Profit | -0.45 | 197.8% | 77.6% |
| OPM | 6.33% | 3.19pp | 6.45pp |
| NPM | -1.61% | 3.26pp | 6.19pp |
| EPS | -0.05 | 200.0% | 78.3% |
Sanara MedTech Reports Q2 2026 Financial Results
12 Aug 2026 · 12 Aug, 1:49 am
Summary
Sanara MedTech Inc. reported second quarter 2026 financial results, with net revenue increasing 9% year-over-year to $28.1 million, supported by a gross margin of 93%. While operating income decreased to $1.8 million and the company posted a net loss from continuing operations of $0.4 million, Adjusted EBITDA saw an increase to $5.0 million. Management highlighted solid revenue growth and the significant subsequent event of an acquisition agreement with MIMEDX, which is expected to create a leading regenerative medicine company.
Key Highlights
- 1
Sanara MedTech Inc. reported net revenue of $28.1 million for the second quarter of 2026, an increase of 9% compared to $25.8 million in the second quarter of 2025.
- 2
Gross profit for the second quarter of 2026 was $26.2 million, representing 93% of net revenue, up from $23.9 million or 92% of net revenue in the prior year's second quarter.
- 3
Operating income for the second quarter of 2026 was $1.8 million, a decrease from $2.5 million in the second quarter of 2025.
- 4
The company reported a net loss from continuing operations of $0.4 million, or a loss of $0.05 per diluted share, for the second quarter of 2026, compared to a net income of $0.5 million, or $0.05 per diluted share, in the second quarter of 2025.
- 5
Adjusted EBITDA for the second quarter of 2026 was $5.0 million, an increase from $4.7 million in the second quarter of 2025.
- 6
For the first six months of 2026, net revenue increased 14% to $55.9 million compared to $49.2 million in the first six months of 2025.
- 7
The company announced its entry into a transformational agreement for its expected acquisition by MIMEDX.
Management Comments
Seth Yon
We continued to drive solid revenue growth in the second quarter of 2026 with net revenue of $28.1 million, representing a 9% increase over the second quarter of 2025, as well as gross margin of 93% supporting Adjusted EBITDA of $5.0 million. Subsequent to the close of the quarter, we announced our entry into a transformational agreement in which Sanara is expected to be acquired by MIMEDX, a leading provider of products for applications in wound care, burn and surgical sectors of healthcare. The transaction is expected to combine Sanara’s pure play surgical focus and innovative technologies across collagen particulate, wound irrigation and bone fixation with MIMEDX’s high-growth, best-in-class surgical portfolio, creating a leading regenerative medicine company across numerous surgical subspecialties. The completion of this combination, which remains subject to customary closing conditions, would allow us to deepen our existing distributor relationships and expand our operating presence by bringing together two highly focused organizations with deep benches of talent and strong momentum in the surgical space. We remain focused on continuing to meet the needs of our customers and expanding penetration of our portfolio of surgical products, which include our leading product CellerateRX Surgical, BIASURGE and OsStic, a licensed synthetic injectable structural bio-adhesive bone void filler which remains on track to be introduced to the market in the first quarter of 2027.
Informational and educational content only. Not investment advice.